Mayne Pharma’s Post

PEI expanding safe use of Biosimilars Prince Edward Island joins several other provinces and territories by expanding the use of biosimilar drug treatments for Island residents. Starting October 12, 2023, patients under the PEI Pharmacare program currently using one of the originator biologics Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade® and Rituxan® will be transitioned to a biosimilar. These patients will have until June 30, 2024 to complete the transition. A switch to biosimilars, while good for provincial healthcare budgets, may also have a significant financial impact on private plans that provide coverage. To maximize support for plan members from provincial plan coverage, private plan sponsors may consider adopting similar provincial initiatives, while continuing to provide safe and effective medication options. If you would like a deeper discussion on this or other issues impacting your group benefits plan, reach out to your Eckler consultant or connect with us at https://www.eckler.ca/ You can find more on the PEI Biosimilar Initiative at https://lnkd.in/g88JCbKr

Arecor Therapeutics plc (AIM:AREC)'s subsidiary Tetris Pharma Limited has partnered exclusively with a company called Goodlife, which will import, market and distribute the diabetes treatment Ogluo in the Benelux region. With the regulatory green light from the Zorginstiuut Nederland, the National Healthcare Institute of The Netherlands, Goodlife is poised to launch Ogluo in the Dutch market by the first half of next year. Chief executive Sarah Howell told investors: "Goodlife provides the commercial expertise and detailed understanding of regional market dynamics that are essential for the company's continued roll-out of Ogluo and its market adoption in the Benelux region. "The upcoming launch in The Netherlands adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as part of the planned ongoing pan-European commercial roll-out for this important product." More at #Proactive #ProactiveInvestors #AIM #AREC #ArecorTherapeutics #TetrisPharma #Goodlife http://ow.ly/X8BA104T98E

BREAKING NEWS: Meitheal Pharmaceuticals Launches Dacarbazine for Injection. Amidst a time of injectable drug shortages, Meitheal is proud to introduce Dacarbazine for Injection, USP 200 mg per vial, NDC – 71288-174-21, now available in a single-dose vial. "We are thrilled to bring Dacarbazine to the United States Market," declared Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. "At Meitheal, we recognize the critical importance of a reliable drug supply. The launch of Dacarbazine exemplifies our steadfast commitment to ensuring sustainability of essential medications in the United States. By delivering on our promises, we empower our customers to effectively meet the needs of their patients." Dacarbazine for Injection, USP is indicated in the treatment of metastatic malignant melanoma, addressing a crucial therapeutic need. This launch underscores Meitheal's dedication to advancing patient care and contributing to the broader healthcare landscape. Learn more about Dacarbazine here: https://lnkd.in/dMBMHunx  Think sustainability, think Meitheal. #Sustainability #Meithal #NewProductLaunch #PatientCare #HealthcareInnovation

The US FDA has given the green light to adalimumab-ryvk (Simlandi), the first interchangeable, high-concentration, citrate-free adalimumab biosimilar. This marks a significant milestone as the 10th adalimumab biosimilar approved by the FDA and the inaugural approval for Alvotech, an Icelandic pharmaceutical company, in collaboration with Teva Pharmaceuticals. Robert Wessman, Chairman and CEO of Alvotech, highlighted the potential market impact of this interchangeable, citrate-free biosimilar in the evolving U.S. biosimilars environment. Adalimumab-ryvk, previously approved in the EU, Australia, and Canada, is indicated for various conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Notably, it is the third Humira biosimilar granted interchangeability status, allowing pharmacists (subject to state law) to substitute it for the reference product without involving the prescribing clinician. This distinguishes it from other biosimilars, which are only interchangeable with the low-concentration formulation of Humira. The imminent launch of Adalimumab-ryvk in the U.S. is eagerly awaited, with details on pricing yet to be disclosed. The biosimilar market continues to evolve, offering new options and potential cost savings for patients. Stay tuned for further updates! LINK:https://lnkd.in/eaxnuMdF #FDAApproval #Biosimilars #HealthcareInnovation

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. Edison Group notes that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the first of two Phase III trials expected to initiate in mid-2024. The company also made positive regulatory and operational strides with its lead antibiotic asset, Zevtera (following FDA approval in April 2024), and Edison eagerly await the announcement of a potential US commercial partner. #biopharmaceuticals #medical #sustainablegrowth https://lnkd.in/d7ATbkC4

BREAKING: Meitheal is pleased to announce the launch of its Leucovorin Calcium for Injection in five presentations: 50 mg per vial in a single-dose vial, 100 mg per vial in a single-dose vial, 200 mg per vial in a single-dose vial, 350 mg per vial in a single-dose vial, and 500 mg per vial in a single-dose vial. Leucovorin Calcium for Injection is indicated after high dose methotrexate therapy in osteosarcoma.   “We are excited to bring Leucovorin to the United States Market during a time of product shortage,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. “At Meitheal, we understand how important it is to have a reliable supply. Launching Leucovorin is just one more example of our ability to follow through on our commitment to our customers and their patients' needs.”   Learn more in today’s news release: https://lnkd.in/gBq5UYGZ   #patientcare #supply #forthecommongood

The US FDA has given the green light to adalimumab-ryvk (Simlandi), the first interchangeable, high-concentration, citrate-free adalimumab biosimilar. This marks a significant milestone as the 10th adalimumab biosimilar approved by the FDA and the inaugural approval for Alvotech, an Icelandic pharmaceutical company, in collaboration with Teva Pharmaceuticals. Robert Wessman, Chairman and CEO of Alvotech, highlighted the potential market impact of this interchangeable, citrate-free biosimilar in the evolving U.S. biosimilars environment. Adalimumab-ryvk, previously approved in the EU, Australia, and Canada, is indicated for various conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Notably, it is the third Humira biosimilar granted interchangeability status, allowing pharmacists (subject to state law) to substitute it for the reference product without involving the prescribing clinician. This distinguishes it from other biosimilars, which are only interchangeable with the low-concentration formulation of Humira. The imminent launch of Adalimumab-ryvk in the U.S. is eagerly awaited, with details on pricing yet to be disclosed. The biosimilar market continues to evolve, offering new options and potential cost savings for patients. Stay tuned for further updates! LINK:https://lnkd.in/eaxnuMdF #FDAApproval #Biosimilars #HealthcareInnovation

The US FDA has given the green light to adalimumab-ryvk (Simlandi), the first interchangeable, high-concentration, citrate-free adalimumab biosimilar. This marks a significant milestone as the 10th adalimumab biosimilar approved by the FDA and the inaugural approval for Alvotech, an Icelandic pharmaceutical company, in collaboration with Teva Pharmaceuticals. Robert Wessman, Chairman and CEO of Alvotech, highlighted the potential market impact of this interchangeable, citrate-free biosimilar in the evolving U.S. biosimilars environment. Adalimumab-ryvk, previously approved in the EU, Australia, and Canada, is indicated for various conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Notably, it is the third Humira biosimilar granted interchangeability status, allowing pharmacists (subject to state law) to substitute it for the reference product without involving the prescribing clinician. This distinguishes it from other biosimilars, which are only interchangeable with the low-concentration formulation of Humira. The imminent launch of Adalimumab-ryvk in the U.S. is eagerly awaited, with details on pricing yet to be disclosed. The biosimilar market continues to evolve, offering new options and potential cost savings for patients. Stay tuned for further updates! LINK:https://lnkd.in/eaxnuMdF #FDAApproval #Biosimilars #HealthcareInnovation

Autoinjectors Market worth $1.7 billion in 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/deAfTQbZ The global autoinjectors market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. Becton, Dickinson and Company Ypsomed AG SHL Medical West Pharmaceutical Services Recipharm Haselmeier, a medmix Brand Owen Mumford Gerresheimer Phillips-Medisize Oval Medical Technologies Ltd Kaléo Solteam Incorporation E3D Elcam Drug Delivery Devices Crossject Johnson Medtech (PART OF Johnson Electric HOLDINGS LTD.) Antares Pharma Inc., INC. (PART OF Halozyme, Inc.) Jabil Healthcare Congruence Medical Solutions AbbVie Amgen Eli Lilly and Company Novartis Merck KGaA, Darmstadt, Germany Viatris INC. (FORMERLY Mylan INC.) Biogen

https://lnkd.in/eqsUz5Ty Key Insights: • Sandoz will distribute Biocon Biologics’ brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), in Australia under the agreement Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #biocon #biosimilars #agreement #collaboration #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights